Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > July 21, 2022
Daily News
July 21, 2022
- Gene Therapy VB-111 Fails in PIII Ovarian Cancer Trial: NanoCarrier
July 21, 2022
- JT’s Tapinarof Cream Safe and Effective for Eczema: Japan PIII Study
July 21, 2022
- Texas Court Favors Seagen in Enhertu Patent Row, Daiichi Sankyo Poised to Challenge Ruling
July 21, 2022
- Japan Plans Smaller Drug Price Survey for 2023 Revision, Just Like 2 Years Ago
July 21, 2022
- Imfinzi, Bavencio to Add Encephalitis Risks in Label Revision
July 21, 2022
- Janssen’s CAR-T Therapy, Kymriah Label Expansion Up for Review on Aug. 3
July 21, 2022
- Novo’s Rybelsus in for Price Cuts as Chuikyo OKs CEA Results
July 21, 2022
- Nuvaxovid Gets Label Update to Allow Primary Inoculations in Ages 12 and Older
July 21, 2022
- Japan Again Takes Pass on Emergency Approval for Shionogi’s COVID Pill as Panels Nix Presumed Efficacy
July 21, 2022
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…